Effects of resveratrol on cancer cachexia in a mouse model by Mansfield, Jessica












Effects of resveratrol on cancer cachexia in a mouse model 
Jessica Mansfield 
The Ohio State University 




























Running Head:  EFFECTS OF RESVERATROL ON CANCER CACHEXIA  2 
Abstract 
Cancer cachexia, characterized by muscle wasting and fatigue, affects many cancer 
patients.  Inflammatory processes are implicated in the pathobiology of cancer 
cachexia.  Resveratrol, a compound found in red grapes, peanuts, and dark chocolate 
has been found to exhibit anti-inflammatory properties.  This study evaluated resveratrol 
as an intervention to decrease or reverse symptoms of muscle wasting and fatigue in 
tumor bearing mice.  In mice, fatigue is measured as decreased voluntary wheel 
running activity (VWRA).  The sample included 4 groups of seven C57BI/6  female 
mice.  Using a quantitative, experimental design, each mouse was housed alone and 
acclimated for 10 days to a running wheel.  Half the mice were injected with Lewis Lung 
Carcinoma cells and half served as healthy controls.  Half the tumor and control mice 
were treated with a slow release pellet planted under the skin designed to deliver 1 
mg/kg/day of resveratrol over 21 days, and half received a placebo pellet.  Wheel 
running activity was measured at day 0, 7, 14, and 19 of tumor growth. At the end of the 
experiment, gastrocnemius muscles were removed and weighed to evaluate muscle 
wasting.  A two-way (tumor drug) analysis of variance was used to determine the effect 
of tumor growth and resveratrol on muscle mass and fatigue.  Analysis showed no 
effects of resveratrol on muscle mass, VWRA, or tumor growth compared to control 
animals.  However, VWRA was significantly correlated with muscle mass.  The data 
indicate that resveratrol at this dose had no effect on muscle wasting or fatigue in 
tumor-bearing mice.  However, loss of muscle mass may directly contribute to fatigue as 
indicated by the correlation between muscle mass and VWRA.  More research is 
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needed to develop effective interventions to reduce muscle wasting, which may reduce 
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Introduction 
Cancer cachexia is a syndrome of progressive weight loss characterized by the 
wasting of body fat and lean muscle, along with fatigue, weakness, and decreased 
appetite (Hemming & Maher, 2005).  Both muscle wasting and fatigue are prevalent 
symptoms experienced by patients.  Cancer patients who suffer from cancer cachexia 
have higher incidences of morbidity and mortality, decreased response to treatment, 
and more adverse effects from cancer treatment (Skipworth, Stewart, Dejong, Preston, 
& Fearon, 2007).  The cause of cancer cachexia is still unknown.  Thus treatments to 
decrease or reverse cachexia have yet to be found.   
One particular process that may contribute to cancer cachexia is the 
inflammatory response.  Tumors induce pro-inflammatory cytokines that activate 
catabolic processes.   These cytokines directly activate the ubiquitin-proteosome 
pathway, which causes myosin degradation, muscle wasting, and decreased muscle 
mass and strength (Skipworth, et al., 2007; Deans, Wigmore, Paterson-Brown, Black, 
Ross, & Fearon, 2005; Cai, et al., 2004).  Resveratrol, a chemically simple compound 
found in red grapes, peanuts, and dark chocolate has been found to exhibit anti-tumor 
and anti-inflammatory effects (Udenigwe, Ramprasath, Aluko, & Jones, 2008).  
Resveratrol may reduce the release of inflammatory cytokines, leading to decreased 
muscle wasting and fatigue.    
 The purpose of this study is to evaluate the effects of resveratrol on muscle 
wasting and fatigue in a mouse model of cancer cachexia.  In mice, fatigue is modeled 
as a decrease in voluntary wheel running activity (VWRA).  Gastrocnemius muscle 
mass will be used as a measure of muscle wasting.  
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 This study is important because cancer is one of the leading causes of death in 
the United States (Centers for Disease Control and Prevention (CDC), 2007), and  
approximately half of all cancer patients experience cancer cachexia during the course 
of their disease.  Futhermore, because cancer survival rates are rising, many more 
people are living with weakness, fatigue, and decreased muscle mass than in previous 
years.  Cachexia is associated with increased morbidity and mortality (Hemming & 
Maher, 2005).  This progressive syndrome affects both the psychological and physical 
well-being of patients, ultimately decreasing their quality of life.  Thus, it is crucial to 
search for interventions that slow down or counteract this wasting process.  
 
Review of Literature 
Cancer cachexia is a progressive syndrome of fatigue, skeletal muscle wasting, 
weight loss, anemia, and anorexia (Argiles, Lopez-Soriano & Busquets, 2007).  In the 
United States, cancer is the second leading cause of death, with 562,875 people dying 
from cancer in 2007 (American Cancer Society, 2010).  According to the American 
Cancer Society, there are over 11 million Americans alive today with a history of cancer 
(2009).  Cancer cachexia affects approximately 50% of these cancer patients during 
their treatment, and is present in close to 100% of cancer patients who die from their 
disease (Norton, Peacock, & Morrison, 1987). As this syndrome progresses, it becomes 
both a physical and psychological burden on the patient, contributing to adverse 
outcomes.  Patients have reported decreased quality of life, decreased response to 
treatment, increased treatment side effects, decreased physical performance, and 
increased mortality rates (Skipworth, Stewart, Dejong, Prestion & Fearon, 2007).  While 
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many different effects of tumor growth are thought to contribute to cachexia, a growing 
body of evidence suggests that activation of the inflammatory system has a major 
influence on the progression of cachexia.   
The pathobiology of cancer cachexia is not fully understood.  However, studies 
have shown cancer cachexia is associated with a tumor-induced activation of pro-
inflammatory cytokines which leads to decreased muscle mass and strength.  Pro-
inflammatory cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor alpha (TNF-α) 
activate the ubiquitin proteolytic pathway, which causes myofibrillar protein degradation 
and muscle wasting (Argiles, Busquets, & Lopez-Soriano, 2006).  Animals given 
supplements of these cytokines demonstrate a characteristic “sickness behavior,” which 
includes decreased activity and food intake, and altered sleep patterns (Wang, 2008).  
TNF-α is associated with the activation of NF-kB, which is a transcription factor that 
increases synthesis and activity of the ubiquitin-proteosome pathway.  In muscle, this is 
associated with increased expression of E3 ubiquitin ligases, muscle atrophy F box 
(MAFbx) and muscle RING finger 1 (MuRF1).  These ligases selectively 
polyubiquininate myosin proteins to be degradated (Dodson, Baracos, Jatoi, Evans, 
Cella, Dalton, & Steiner, 2011). Expression of MAFbx and MuRF1 is increased in animal 
models of muscle wasting (Dodson et. al, 2011).  Additionally, studies have found 
elevated levels of pro-inflammatory biomarkers in cancer patients (Wang, 2008).  Thus, 
increased cytokine levels are associated with muscle degradation and fatigue in 
cachexia patients.   
 Evidence from animal models of cancer cachexia suggests that down regulation 
of the inflammatory response may decrease or reverse muscle wasting and fatigue in 
Running Head:  EFFECTS OF RESVERATROL ON CANCER CACHEXIA  7 
tumor-bearing animals.  Previous studies indicate that non-steroidal anti-inflammatory 
drugs (NSAIDs) may preserve muscle mass and body weight in tumor-bearing mice 
(Mantovani & Madeddu, 2008).   This evidence leads us to believe that other 
substances that suppress the inflammatory response may also decrease cachexia. 
 Resveratrol is a compound found in red grapes, dark chocolate, red wine, and 
peanuts, among others, that exhibits anticancer, antioxidant, and anti-inflammatory 
properties (Udenigwe, Ramprasath, Aluko, & Jones, 2008).  Japanese folk-medicine 
has utilized resveratrol in the treatment of inflammatory diseases for many years (Kubo, 
et. al, 1981).  Resveratrol has the potential to control muscle wasting and fatigue by:  1.) 
decreasing or reversing tumor growth, and 2.) decreasing or reversing the inflammatory 
process.   
Many studies have shown that resveratrol possesses anticancer properties in 
both animal models and in cultured human tumor cells by stimulating cancer cell death 
(Udenigwe, Ramprasath, Aluko, & Jones, 2008).  By decreasing tumor size or 
increasing tumor apoptosis, resveratrol may decrease the amount of inflammatory 
cytokines released in response to tumor growth, and therefore, decrease muscle 
wasting and fatigue.  Also, studies have shown that resveratrol blocks activation of NF-
kB and decreases cytokine synthesis in response to stimulation of the inflammatory 
response (Wyke, Russell & Tisdale, 2004).   
NF-kB activation is associated with tumor cell survival and increased muscle 
wasting (Baldwin, 2001).  By interfering with the activation of NF-kB, resveratrol has the 
potential to decrease the activation of the ubiquitin proteosome pathway that leads to 
muscle degradation.   Many studies have shown that resveratrol has the ability to 
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suppress TNF-α (Das & Das, 2007).  By suppressing the release of TNF-α, resveratrol 
may inhibit release of NF-kB, and therefore inhibit activation of the ubiquitin-proteosome 
pathway, which leads to myofibrillar degradation.   A study by Singletary et al. showed 
that grape juice concentrate delayed the onset of tumors in mice (2003-double check 
citation).   Another study, by Wyke, Russell, and Tisdale, showed that resveratrol 
attenuated both weight loss and muscle protein degradation in tumor-bearing mice 
(2004).  Thus, the question addressed by this study is:  Would resveratrol supplements 
decrease or prevent  muscle wasting  and  reduce  fatigue in tumor-bearing mice 
compared to mice who are not given the supplement? 
 









Muscle Wasting/Fatigue  
 
Methods 
This study was a quantitative, experimental design using 28 age-matched adult 
C57BI/6 female mice which were divided into 4 groups:  Tumor, Tumor + Resveratrol, 
Control, and Control + Resveratrol.  Each mouse was housed individually, and  
acclimated to the environment for 10 days.  One half of the mice were inoculated 
subcutaneously between the scapulae with 5x105 Lewis Lung Carcinoma tumor cells in 
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0.2 ml saline; controls were injected with 0.2 ml saline. Growth of the tumor between the 
scapulae does not impair the locomotor ability of the mice.  One half the tumor-injected 
and one half the saline injected animals were implanted  with a pellet designed to 
release 1 mg/kg/day resveratrol, over 21 days,  and one half received a placebo pellet 
of the same size.  Mice were weighed and food and water intake were measured on day 
0, 7, 14, and 19.   
 
Measurement of muscle wasting 
For each mouse, the two gastrocnemius muscle were dissected and weighed at 
the time of sacrifice.  Muscle weight was calculated as the average of the two muscles.  
Because muscle mass is expected to be less in smaller animals, relative gastrocnemius 
mass was determined by dividing average muscle weight by body weight.   
 
Measurement of inflammation 
Systemic inflammation in the mice was determined by dissecting and measuring 
spleen weight at the time of sacrifice.  With increased inflammatory activity, the spleen 
increases in size and weight.   
 
Measurement of Fatigue 
Fatigue was modeled as a decline in the voluntary wheel running activity (VWRA) 
of the mice.  Healthy mice can run up to 2 miles during the night.  As muscle wasting 
proceeds, the mice run for less amount of time.  VWRA was measured using a system 
triggered by a magnet embedded in the wheel that tripped a switch connected to a 
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signal processor and connected to a computer programmed to continuously record the 
total number of wheel turns in a preset period of time.  VWRA was measured at days 0, 
7, 14, and 19 of tumor growth.  To control for individual variations in VWRA, the change 
in VWRA from days 7 to 14, and days 14-19 was also calculated.   
 
Measure of Biomarkers 
  MAFbx and MURF1 are biomarkers that indicate muscle wasting.  To measure 
these biomarkers, total RNA was extracted from 100 mg of frozen gastrocnemius 
muscle in 1 ml of TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's 
instructions.  1 μg RNA was treated with DNase 1 (Invitrogen) and reverse transcribed 
to cDNA using the Iscipt cDNA synthesis kit (BioRad). Real time PCR was performed 
using primer pairs for MAFbx and MURF1.  All reactions were performed in duplicate 
using 25 ng of cDNA in a final reaction volume of 25 μl using the iCycler iQ5 (BioRad). 
The reaction conditions were 95 °C for 15 s and 60 °C for 1 min for 40 cycles after the 
initial denature at 95 °C for 10 min. The results for MAFbx and MURF1 were normalized 
to GAPDH and expressed as 2 CT (normalized expression ratio). 
 
Statistical Analysis 
Data was analyzed using two way (tumor/drug) analysis of variance.  Bivariate 
correlations between the dependent variables were also analyzed using SPSS version 
16.  
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Results 
As shown in Figure 1, tumor had a significant effect on muscle mass (p < 0.001).  
Resveratrol had no effect on gastrocnemius muscle mass (p=0.38).  These findings 
suggest that this dose of resveratrol did not affect the mechanisms responsible for 
tumor-induced muscle wasting.    However, resveratrol had a different effect on muscle 
mass in tumor bearing and control mice (p = 0.03). 
As shown in Figure 2, tumor had a significant effect on spleen weight (p=0.005). 
This reflects an increased inflammatory response induced by the tumor.  Resveratrol 
had no effect on spleen weight (p=0.88).    
Neither tumor growth or resveratrol had a significant effect on VWRA.  However, 
when day 19 wheel counts were subtracted from day 14 wheel counts to produce a 
measure of change in VWRA, there was a significant effect of tumor growth on VWRA 
(p=0.009), but not resveratrol.  Tumor mice VWRA declined by 182 turns, while control 
mice VWRA increased by 752 turns.  
As shown in table 1, there was a significant negative correlation between spleen 
weight and relative gastrocnemius weight (r= -0.68) and between spleen weight and 
VWRA (r=   -0.67), supporting the premise that systemic inflammatory response 
(increased spleen weight) contributes to skeletal muscle wasting (decreased muscle 
mass), and fatigue (decreased VWRA).  There was also a significant positive correlation 
between muscle mass and VWRA, supporting the premise that muscle wasting 
contributes to fatigue.  
As shown in figures 3 and 4, expression of both MAFbx and MURF1 mRNA were 
increased in gastrocnemius muscles of tumor-bearing mice.  This would explain in part 
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the smaller muscle mass in the tumor-bearing mice.  Additionally, as shown in table 1, 
expression of these biomarkers of myosin degradation were positively correlated with 
spleen weight, and negatively correlated with relative gastrocnemius weight, supporting 
the idea that inflammation plays a key role in tumor-induced muscle wasting.   
 
Figure 1 
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Relative Gastroc  1 -0.68 0.58 -0.56 -0.71 
Spleen Weight  1 -0.5 0.90 0.71 
VWRA Day 19   1 -0.31 -0.20 
MAFbx    1 0.84 
MURF1     1 
 




Cancer cachexia affects more than half of all cancer patients, causing weakness 
and fatigue, which contributes to worse outcomes and decreased quality of life.  
Although there is no specified cause of cachexia, studies suggest that an increased 
inflammatory process contributes to the disease process.  Our study revealed that 
tumor bearing mice developed enlarged spleens over the course of the project, 
suggesting that the inflammatory response is triggered by the presence of tumor.  
Moreover, the tumor-bearing mice had smaller muscle mass, indicative of skeletal 
muscle wasting associated with cancer cachexia.  Though resveratrol has been shown 
to have anti-inflammatory effects in previous studies, we found that resveratrol at 1 
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mg/kg/day did not have an effect on spleen size or muscle wasting in our mouse model 
of cancer cachexia.   
In mice, fatigue is modeled as reduced voluntary wheel running.  In the present 
study, there was a wide range of VWRA between mice, but no significant group 
differences in VWRA were detected.  However, when day 19 wheel counts were 
subtracted from day 14 wheel counts to produce a measure of change in VWRA, VWRA 
was significantly less in the tumor-bearing mice when compared to the control mice.   
Furthermore, VWRA was significantly correlated with spleen size and muscle 
mass, supporting an association between the inflammatory response in tumor-induced 
muscle wasting and fatigue.  The collective data suggests that repeating this study 
using increased doses of resveratrol may be useful in determining whether the anti-
inflammatory actions of resveratrol on cancer cachexia as demonstrated in previous 
studies have an effect.  Further studies are needed to explore the cause of cancer 
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